Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dabigatran
Drug ID BADD_D00563
Description Dabigatran is the active form of the orally bioavailable prodrug [dabigatran etexilate].
Indications and Usage Not Available
Marketing Status approved; investigational
ATC Code B01AE07
DrugBank ID DB14726
KEGG ID D09707
MeSH ID D000069604
PubChem ID 216210
TTD Drug ID D0M7JT
NDC Product Code 51869-0030
UNII I0VM4M70GC
Synonyms Dabigatran | N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine | BIBR 1048 | Pradaxa | Dabigatran Etexilate | Etexilate, Dabigatran | Dabigatran Etexilate Mesylate | Etexilate Mesylate, Dabigatran | Mesylate, Dabigatran Etexilate
Chemical Information
Molecular Formula C25H25N7O3
CAS Registry Number 211914-51-1
SMILES CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intracranial mass17.11.01.0170.000979%Not Available
Abdominal incarcerated hernia07.16.06.0090.000367%Not Available
Anisocoria17.02.11.009; 06.05.03.0130.000245%Not Available
Anticoagulant-related nephropathy24.07.07.005; 20.05.03.023; 12.03.01.0600.000367%Not Available
Aortic dissection rupture24.02.03.0060.000245%Not Available
Atheroembolism24.01.01.037; 12.02.05.0520.000245%Not Available
Blood loss anaemia24.07.01.088; 01.03.02.0180.007707%Not Available
Cardiac dysfunction02.11.01.0040.000245%Not Available
Carotid arterial embolus24.01.04.018; 17.08.01.0670.000245%Not Available
Catheter site haematoma24.07.01.090; 12.07.02.020; 08.02.02.0200.000245%Not Available
Cerebellar stroke17.08.01.070; 24.04.06.0460.000245%Not Available
Cerebral mass effect17.11.01.0190.001835%Not Available
Cerebral microangiopathy24.03.05.016; 17.08.02.0310.000245%Not Available
Colorectal adenoma07.20.01.019; 16.05.02.0090.000245%Not Available
Dilated cardiomyopathy02.04.01.0170.000734%Not Available
Disease complication08.01.03.0870.000734%Not Available
Eosinophilic granulomatosis with polyangiitis24.12.04.010; 22.01.01.025; 10.02.02.031; 01.02.04.0220.000245%Not Available
Femoral hernia incarcerated07.16.07.0020.000245%Not Available
Gallbladder rupture12.01.17.005; 09.03.02.0120.000734%Not Available
Gastrointestinal angiectasia24.03.03.048; 07.15.04.0090.000245%Not Available
Gastrointestinal vascular malformation haemorrhagic24.07.02.064; 07.15.04.0100.000612%Not Available
Giant cell arteritis24.12.02.003; 17.08.02.033; 10.02.02.032; 06.07.02.0100.000245%Not Available
Haemodynamic rebound24.03.02.036; 08.06.02.0240.000245%Not Available
Haemoperitoneum24.07.02.065; 12.01.17.007; 07.07.02.0070.002569%Not Available
Hepatic vein dilatation24.03.04.014; 09.01.06.0280.000245%Not Available
Iliac artery embolism24.01.02.0140.000245%Not Available
Iliac artery occlusion24.04.03.0160.000245%Not Available
Incarcerated inguinal hernia07.16.02.0050.000489%Not Available
Incarcerated umbilical hernia07.16.03.0040.000245%Not Available
Malignant anorectal neoplasm16.13.01.021; 07.21.05.0060.000245%Not Available
The 21th Page    First    Pre   21 22    Next   Last    Total 22 Pages